WO2021094989A1 - Homeopathic topical composition - Google Patents
Homeopathic topical composition Download PDFInfo
- Publication number
- WO2021094989A1 WO2021094989A1 PCT/IB2020/060686 IB2020060686W WO2021094989A1 WO 2021094989 A1 WO2021094989 A1 WO 2021094989A1 IB 2020060686 W IB2020060686 W IB 2020060686W WO 2021094989 A1 WO2021094989 A1 WO 2021094989A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- homeopathic
- solution
- natrum
- topical
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 90
- 230000001632 homeopathic effect Effects 0.000 title claims abstract description 52
- 230000000699 topical effect Effects 0.000 title abstract description 20
- 235000000470 Vitis quadrangularis Nutrition 0.000 claims abstract description 27
- 235000001506 Ledum palustre Nutrition 0.000 claims abstract description 22
- 241000007443 Lobaria pulmonaria Species 0.000 claims abstract description 22
- 244000071109 Terminalia arjuna Species 0.000 claims abstract description 22
- 235000000538 Terminalia arjuna Nutrition 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- 241000227142 Rhododendron tomentosum Species 0.000 claims abstract description 21
- 241001136643 Gelsemium sempervirens Species 0.000 claims abstract description 17
- 241000189665 Colchicum autumnale Species 0.000 claims abstract description 16
- 244000045483 Cissus quadrangularis Species 0.000 claims abstract 6
- 239000000243 solution Substances 0.000 claims description 53
- 238000009472 formulation Methods 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 12
- 239000006185 dispersion Substances 0.000 claims description 12
- 229910052749 magnesium Inorganic materials 0.000 claims description 12
- 239000011777 magnesium Substances 0.000 claims description 12
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 claims description 12
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 11
- 239000008213 purified water Substances 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 8
- 239000000499 gel Substances 0.000 claims description 8
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 6
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 6
- 239000012676 herbal extract Substances 0.000 claims description 6
- 235000008216 herbs Nutrition 0.000 claims description 6
- 229940041616 menthol Drugs 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- -1 Natrum phosphoric Chemical compound 0.000 claims 1
- 229940100611 topical cream Drugs 0.000 claims 1
- 229940042129 topical gel Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 16
- 239000000284 extract Substances 0.000 abstract description 15
- 208000002193 Pain Diseases 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000036407 pain Effects 0.000 abstract description 10
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 229940041677 topical spray Drugs 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 5
- 238000000605 extraction Methods 0.000 abstract description 4
- 239000011885 synergistic combination Substances 0.000 abstract description 2
- 210000002683 foot Anatomy 0.000 description 23
- 244000262406 Vitis quadrangularis Species 0.000 description 21
- 229940098465 tincture Drugs 0.000 description 16
- 230000036515 potency Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 9
- 235000010418 carrageenan Nutrition 0.000 description 9
- 239000000679 carrageenan Substances 0.000 description 9
- 229940113118 carrageenan Drugs 0.000 description 9
- 229920001525 carrageenan Polymers 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 9
- 241000723375 Colchicum Species 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 8
- 241001113926 Gelsemium Species 0.000 description 7
- 230000008961 swelling Effects 0.000 description 6
- 239000012895 dilution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000208422 Rhododendron Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 2
- 241001355260 Cissus Species 0.000 description 2
- 235000017003 Cissus Nutrition 0.000 description 2
- 235000017014 Cissus repens Nutrition 0.000 description 2
- 244000251855 Ledum palustre Species 0.000 description 2
- 241000218922 Magnoliophyta Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 238000010149 post-hoc-test Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- JSUVCAQGWVUMPD-QXUQJYLISA-N Arjuna Natural products O([C@H]([C@@H](O)C=O)[C@H]1[C@H](O)COC(=O)c2c(c(O)c(O)c(O)c2)-c2c(O)c(O)c3OC(=O)c4c(c(O)c(O)c5OC(=O)c2c3-c45)-c2c(O)c(O)c(O)cc2C(=O)O1)C(=O)c1cc(O)c(O)c(O)c1 JSUVCAQGWVUMPD-QXUQJYLISA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000208421 Ericaceae Species 0.000 description 1
- VJWIXTLPDOVKPN-UHFFFAOYSA-N Gelsemine Natural products CN1CC2(C=C)C3CC4OC3C1C2CC45C(=O)Nc6ccccc56 VJWIXTLPDOVKPN-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 235000000386 Ledum groenlandicum Nutrition 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 241000195954 Lycopodium clavatum Species 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010073713 Musculoskeletal injury Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 231100000159 OECD 404 Acute Dermal Irritation/Corrosion Toxicity 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- UQVUEULZDJRMJR-UHFFFAOYSA-N Sempervirine Chemical compound C1=CC2=C3C=CC=CC3=NC2=C2N1C=C1CCCCC1=C2 UQVUEULZDJRMJR-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 241000975373 Sticta Species 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241000159243 Toxicodendron radicans Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000573 anti-seizure effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- NFYYATWFXNPTRM-QJICHLCESA-N gelsemine Chemical compound OC1=NC2=CC=CC=C2[C@@]21[C@H]1[C@H]3[C@H]4CO[C@@H]2C[C@H]4[C@]1(C=C)CN3C NFYYATWFXNPTRM-QJICHLCESA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000037231 joint health Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000000796 marsh Labrador tea Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- QGSZPWIANAPIKL-UHFFFAOYSA-N sempervirine Natural products C1CC=C2C=C3N(CC=C4C3=Nc5ccccc45)C=C2C1 QGSZPWIANAPIKL-UHFFFAOYSA-N 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000130 skin irritation / corrosion testing Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Definitions
- the present invention relates to a novel homeopathic composition useful for treating pain and/or inflammation comprising tinctures and/or diluted extracts. More particularly, there is provided a composition which contains a synergistic combination of extracts from Terminalia arjuna, Sticta pulmonaria, Colchicum autumnale, Gelsemium sempervirens, Ledum Palustre and Cissus quadrangularis .
- the present invention also provides a method of preparation of the homeopathic drug composition for topical application as gel or cream preferably as topical spray composition.
- One of the basic tenets of homeopathic medicine is that a cure for a disease can be evoked by using a high dilution medicine that resembles, yet is different from, the cause of the disease. Further, topical Allopathic medicines for pain management may have associated side effects like skin irritation and redness.
- RU02153348 disclose homeopathic drug for treatment of polyarthritis, arthrosis, rheumatism, containing Rhus toxicodendron and colchinicum autumnale differing in that it additionally contains Lithium carbonicum, Hepar sulfuris, Lycopodium clavatum, and Calcarea fluorica.
- the present invention relates to a new homeopathic composition prepared by using dilute concentrations of substances that modify the frequency of the diluent and produce a corresponding response in the human or animal body when taken externally as a topical administration, specifically a spray composition.
- Homeopathic compositions have been described as being effective by delivering a small amount of a substance that in large quantities would create the symptom being observed thereby allowing the body to properly develop a response that ultimately is able to eliminate the cause of the symptom being observed.
- a wide variety of conditions as noted are treated using the homeopathic compositions, including back ache, muscle stiffness, pain reduction, swelling, inflammation, joint pain, localized musculoskeletal injuries like sprain, strains and many others.
- the invention provides a homeopathic composition
- a homeopathic composition comprising; i) Terminalia arjuna 2x to 8x; ii) Sticta pulmonaria 2x to 8x; iii) Colchicum autumnale 2x to 8x; iv) Gelsemium sempervirens 2x to 8x; v) Ledum palustre 2x to 8x; and vi) Cissus quadrangularis 2x to 8x.
- the invention provides a homeopathic topical composition comprising:
- tinctures and/or homeopathic preparations of herbal extracts selected from the group consisting of Terminalia arjuna, Sticta pulmonaria, Colchicum autumnale, Gelsemium sempervirens, Ledum palustre and Cissus quadrangularis, (ii) biochemics; and
- the homeopathic composition comprises: (i) tinctures and/or homeopathic preparations of herbal extracts selected from the group consisting of Terminalia arjuna, Sticta pulmonaria, Colchicum autumnale, Gelsemium sempervirens, Ledum palustre and Cissus quadrangularis,
- biochemics selected from Natrum muriaticum, Natrum phosphoricum; Magnesium phosphoricum or Natrum sulphuricum;
- the present invention provides a method of preparation of the homeopathic topical composition; comprising the steps of: a) Mixing the coarse powder of herbs ( Terminalia arjuna, Colchicum autumnale, Gelsemium sempervirens, Ledum palustre and Cissus quadrangularis ) with 70 % dispensing alcohol and 30 % purified water, setting the mixture in a glass column at room temperature and sealing the mouth of the column and setting aside for 48 hours; b) Adding Sticta pulmonaria under constant stirring to solution of step a; c) adding Natrum muriaticum to the solution of step b) under constant stirring; d) adding a secondary non-aqueous solution of Natrum phosphoricum with stirring for 5 - 10 minutes to the solution of step c); e) adding dispensing alcohol and allowing to disperse in the solution of step d); f) filtering the dispersion as obtained in step e) to obtain a clear solution of the composition; and g) adding
- the homeopathic composition of the present invention is filled in containers fitted with spray nozzle. In another aspect the homeopathic composition of the present invention is dispensed in cream, ointment or gel base.
- the homeopathic topical composition are useful in treating pain and/or inflammation, particularly to heal muscular and bone injuries.
- Another aspect of the invention is a method of treating pain by administering an effective amount of a homeopathic topical composition to a subject in need thereof.
- tincture and “homeopathic formulation” of an herb refer to extracts of a part, combinations of parts and/or the entirety of the herb as described in Homeopathic Pharmacopoeia of India.
- the “tincture” can be prepared by exposing a part, parts and/or the entirety of the herb in a solvent, e.g. alcohol, glycerin and/or water.
- the “tincture” of an herb preferably is a mother tincture of the herb prepared according to the procedures in Homeopathic Pharmacopoeia of the United States (HPUS).
- the "homeopathic preparation” can be prepared by dilution of the "tincture” with an appropriate liquid such as water or alcohol.
- the "homeopathic preparation" of an herb for the formulation of the invention is preferably prepared as per HPUS procedures, wherein the mother tincture of the herb is serially diluted and subjected to succession according to the target potency using potentization procedures known in the art of homeopathy.
- potency is defined as the strength of a homeopathic remedy which is determined by how many times the remedy has been succussed and diluted during preparation. A number and a letter are associated with the remedy name to indicate which potency scale has been used.
- An example of the decimal scale would be Arnica Montana 6x.
- An example of the centesimal scale would be Arnica Montana 30c.
- An example of the 50 millesimal scale (LM) would be Arnica Montana LM1.
- an active drug at a potency of lx means that a tincture, preferably as defined in HPUS, of the active drug is diluted 1 in 10, e.g.
- a potency of 2x means that the active drug having a potency of lx is further diluted 1 in 10 and then succussed at least 10 times yielding the active drug at 2x.
- herbal extracts are selected from the group consisting of but not limited to Terminalia arjuna, Sticta pulmonaria, Colchicum autumnale, Gelsemium sempervirens, Ledum palustre and Cissus quadrangularis.
- the extracts of these herbs at the potencies disclosed below are used as active ingredients, which are mixed and blended with other ingredients in a vehicle to form a homeopathic composition.
- the potency of each one of the plurality of active ingredients included in the actives portion may be one of between about tincture to about 100x , between about 1 C to about 30 C, or about LM-1 to about LM-3.
- the potency of each one of the plurality of active ingredients included in the actives portion may be 8x , preferably 2x to 8x.
- a topical spray of instant homeopathic composition may include plurality of active ingredients i.e. tinctures and/or homeopathic preparations and biochemics; and a base including a plurality of inactive ingredients.
- the plurality of active ingredients include tinctures and/or homeopathic preparations of Terminalia arjuna, Sticta pulmonaria, Colchicum autumnale, Gelsemium sempervirens, Ledum palustre and Cissus quadrangularis; and biochemics selected from Natrum muriaticum, Natrum phosphoric or Magnesium phosphoricum, Natrum sulphuricum, or Calcarea sulphurica; preferably Natrum muriaticum and Natrum phosphoricum.
- topical spray homeopathic formulations may include one, all, or any of the following:
- the active ingredients include tinctures and/or homeopathic preparations selected from the group consisting of but not limited to herbal extracts selected from the group consisting of but not limited to Terminalia arjuna, Sticta pulmonaria, Colchicum autumnale, Gelsemium sempervirens, Ledum palustre and Cissus quadrangularis ; and biochemics selected from Natrum muriaticum, Natrum phosphoricum, Magnesium phosphoricum, Natrum sulphuricum, or Calcarea sulphurica.
- herbal extracts selected from the group consisting of but not limited to Terminalia arjuna, Sticta pulmonaria, Colchicum autumnale, Gelsemium sempervirens, Ledum palustre and Cissus quadrangularis ; and biochemics selected from Natrum muriaticum, Natrum phosphoricum, Magnesium phosphoricum, Natrum sulphuricum, or Calcarea sulphurica.
- Terminalia arjuna is a well known medicinal plant used in the ancient medicine.
- the bark of the tree is reported to contain many bioactive compounds, which can be tapped for use in the treatment of many diseases.
- Vagbhata mentions arjuna in the treatment of wounds, hemorrhages and ulcers, applied topically as a powder.
- Sticta pulmonaria is used in inflammatory rheumatism of the knee joint.
- Colchicum autumnale (Colchicum) is a toxic autumn-blooming flowering plant .
- Gelsemium sempervirens ( Gelsemium ) is a twining vine native to warm temperate and tropical America, from Guatemala north to the southeastern USA. All parts of this plant contain the toxic strychnine-related alkaloids gelsemine, gelseminine and sempervirine . At pharmacological doses, G. sempervirens has been reported to show sedative, analgesic and anti- seizure properties.
- Ledum palustre Commonly known as marsh Labrador tea, northern Labrador tea or wild rosemary, is a flowering plant in the subsection Ledum of the large genus Rhododendron in the family Ericaceae. All parts of the plant contain poisonous terpenes that affect the central nervous system a very valuable remedy for rheumatism
- Cissus quadrangularis a traditional medicine for joint and bone health (as well as various feminine disorders and menopause), and shows promise in promoting bone growth rates. It is popular as a joint aid for athletes, with preliminary evidence supporting this property of cissus.
- the process of Cissus quadrangularis extraction used in the composition is cold extraction.
- Dried Cissus quadrangularis is cleaned and macerated into pieces. 100 gm of Cissus is sonicated with alcohol and water at room temperature, post it settling down it is set in open column with Ethanol and Water if required, the column is set sealed. Post 36 hours the elute is collected and sieved. It is filtered using vaccum filtration post 24 hrs.
- the inactive ingredients include menthol, alcohol, glycerin and water.
- Magnesium phosphoricum, Natrum sulphuricum, Calcarea sulphurica are used as it brings in synergistic effect along with the herbs.
- topical preparations include ointment, cream, gel, spray, etc.
- the most preferred being application being topical spray for treating pain and/or inflammation.
- the topical spray compositions of present invention may be applied onto the skin by using a sprayable dispensing device.
- a sprayable dispensing device Preferably, dispensed in a container such as a bottle or the like, fitted with a pump dispenser / nozzle or a manual metered pump that delivers a metered unit dose on actuation.
- the composition of the present invention contains a thickening agent or polymeric material dissolved or suspended in a liquid to yield a gel based composition.
- the observed effectiveness of a given homeopathic preparation can depend upon the method used to administer it to the patient. For example, lower potency (higher concentration) homeopathic ingredients appear to have better results when used as a topical treatment application when compared to high potency ingredients. In contrast, high potency homeopathic ingredients work well when administered orally or internally.
- Table 1 is a listing of all active ingredients (components) that may be used in the various preparations of the instant invention along with the range of dilutions that may be utilized for each.
- tincture refers to the mother tincture as defined in the HPUS.
- a homeopathic composition comprising i) Terminalia arjuna 2x to 8x; ii) Sticta pulmonaria 2x to 8x; iii) Colchicum autumnale 2x to 8x; iv) Gelsemium sempervirens 2x to 8 x; v) Ledum palustre 2x to 8x; and vi) Cissus quadrangularis 2 x to 8 x.
- the composition may comprise biochemics and pharmaceutically acceptable vehicle or carrier.
- composition of the present invention is an effective formulation that does not have toxicity and tackles pain and inflammation effectively.
- the present invention i) all the herbs namely Terminalia arjuna, Sticta pulmonaria, Colchicum autumnale, Gelsemium sempervirens, LedumP alustere and Cissus quadrangularis are measured to 50 gm individually. Columns are setup and each herb is set in the column with purified water and alcohol in ratio of 30:70. The columns are sealed pack and kept for 48 hours. ii) Biochemics like Natrum muriaticum, Natrum phosphoricum, Magnesium phosphoricum, Natrum sulphuricum, Calc area sulphurica are added to the column of Cissus quadrangularis. iii) Elute is filtered.
- the present invention relates to a process for the preparation of a homeopathic topical composition
- a process for the preparation of a homeopathic topical composition comprising the steps of: a) Mixing the coarse powder of herbs ( Terminalia arjuna, Colchicum autumnale, Gelsemium sempervirens, Ledum palustre and Cissus quadrangularis) with 70 % dispensing alcohol and 30 % purified water, setting the mixture in a glass column at room temperature and sealing the mouth of the column and setting aside for 48 hours; b) adding Sticta pulmonaria under constant stirring to solution of step a) c) adding Natrum muriaticum to the solution of step b) under constant stirring; d) adding a secondary non-aqueous solution of Natrum phosphoricum with stirring for 5 - 10 minutes to the solution of step c); e) adding dispensing alcohol and allowing to disperse in the solution of step d); f) filtering the dispersion as obtained in step e) to
- glycerin is added to the clear solution of step f) which is sonicated and filtered to obtain the composition.
- the topical composition of Homeopathy composition Procedure a. 200 ml of Cissus quadrangularis extract made in House and 100 ml of Ledum Palustre added in a beaker, b. Half of 50 ml each of ⁇ Magnesium phosphoricum + Natrum sulphuricum + Calcarea sulphurica ⁇ was added to it (liquids), c. Dispensing Alcohol (70%) + Purified Water (30%) was added, d. The resulting solution was allowed to attain a temperature of 20- 25°C. e. The dispersion as obtained in step (d) was homogenized for 15 minutes at 4200 rpm and stirred for 120 minutes and filtered one or more times through PES filter to obtain a clear solution,
- the topical composition of Homeopathy composition is a topical composition of Homeopathy composition
- Example 3 The topical composition of Homeopathy composition
- step (k) Glycerin was added to the solution to increase the viscosity. k.
- the resulting solution was allowed to attain a temperature of 20- 25°C. l.
- the dispersion as obtained in step (k) was sonicated for 15 minutes stirred for 120 minutes and filtered one or more times through PES filter to obtain a clear solution.
- the clear solution obtained above is filled in spray bottles.
- the composition of the present invention is applied topically by means of a spray.
- the clear solution obtained above is mixed with gel base for topical administration.
- the clear solution obtained above is mixed with cream base for topical administration.
- the formulations according to the present invention exhibited significant decrease of % swelling of the paw compared to the control.
- the % inhibition of the edema formation by the formulations was maximum with VP2, which is in range of 44.82% to 53.31.
- Analgesic activity was evaluated against hypernociception induced in the hindpaw by the administration of an intraplantar carrageenan suspension and was measured according to the paw pressure tests of Randall Selitto.
- Randall Selitto test an analgesy-meter with a cone-shaped paw-presser with a rounded tip, which applies a linearly increasing force to the plantar surface of the paw, was used.
- the weight in grams (g) required to elicit nociceptive responses such as paw flexion or struggling was defined as the nociceptive threshold.
- the mechanical evaluation of hypernociception intensity was evaluated 3 hrs after the carrageenan injection.
- the acute dermal irritation study was performed in accordance with the OECD Guidelines 404 for “Acute dermal irritation/corrosion” on male White New Zealand rabbits (2.5-3 kg). Briefly, approximately 24 hours before the test, around 5 cm x 5 cm of rabbit’s dorsal area of the trunk was clipped for experimental use.
- 0.5 ml formulation was then applied under a 2.5 cm x 2.5 cm gauze patch and wrapped with occlusive dressing.
- the test sites were observed and scored for erythema and oedema at 1 h, 24 h, 48 and 72 h post-exposure with formulation.
- Dermal responses were determined in accordance with OECD guidelines. Erythema and oedema were scored on a scale of 0-4, with 0 showing no effect and 4 representing severe symptoms. Since formulation was expected to be safe, limit test was performed in one rabbit as per OECD guideline 404.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a novel homeopathic composition useful for treating pain and/or inflammation comprising tinctures and/or diluted extracts. More particularly, there is provided a composition which contains a synergistic combination of extracts from Terminalia arjuna, Sticta pulmonaria, Colchicum autumnale, Gelsemium sempervirens, Ledum Palustre and Cissus quadrangularis. The present invention also provides a method of preparation of the homeopathic drug composition as topical preparation, preferably as topical spray composition. Cissus quadrangularis extraction is also a novel process used in the composition where in cold extraction is applied for Cissus Quadrangularis.
Description
HOMEOPATHIC TOPICAL COMPOSITION
Field of the Invention
The present invention relates to a novel homeopathic composition useful for treating pain and/or inflammation comprising tinctures and/or diluted extracts. More particularly, there is provided a composition which contains a synergistic combination of extracts from Terminalia arjuna, Sticta pulmonaria, Colchicum autumnale, Gelsemium sempervirens, Ledum Palustre and Cissus quadrangularis . The present invention also provides a method of preparation of the homeopathic drug composition for topical application as gel or cream preferably as topical spray composition.
Background of the invention
The history of homeopathy dates back to the eighteenth century and the research of the German physician Samuel Hahnemann, who postulated the principle of “like cures like.” In the nineteenth century, Hugo Paul Friedrich Schultz postulated that toxins can have the opposite effect in small doses compared to large doses. In 1888, Schultz showed that very low concentrations of yeast toxins increased yeast growth over 100 fold. At the same time, the psychiatrist Rudolph Arndt developed his “Basic Law of Biology,” which states that weak stimuli slightly accelerate the vital activity, middle-strong stimuli raise it, strong stimuli suppresses it, and very strong stimuli halt vital activity. These separate observations were formulated by Arndt in 1888 into one of the earliest laws of pharmacology representing the homeopathic effect, the Arndt-Schultz rule, which states: every stimulus on a living cell elicits an activity, which is inversely proportional to the intensity of the stimulus. This law was later restated by Ferdinand Hueppe as: for every substance, small doses stimulate, moderate doses inhibit, and large doses kill.
Allopathic medicine, with its emphasis on moderate drug doses, works to inhibit undesired physical symptoms and to kill undesired pathogens too. Homeopathic medicine, on the other hand, begins with small doses and moves towards progressively higher dilutions to stimulate the body's own natural electromagnetic forces. One of the basic tenets of homeopathic medicine is that a cure for a disease can be evoked by using a high dilution medicine that resembles, yet is different from, the cause of the disease. Further, topical Allopathic medicines for pain management may have associated side effects like skin irritation and redness.
RU02153348 disclose homeopathic drug for treatment of polyarthritis, arthrosis, rheumatism, containing Rhus toxicodendron and colchinicum autumnale differing in that it additionally contains Lithium carbonicum, Hepar sulfuris, Lycopodium clavatum, and Calcarea fluorica.
The present invention relates to a new homeopathic composition prepared by using dilute concentrations of substances that modify the frequency of the diluent and produce a corresponding response in the human or animal body when taken externally as a topical administration, specifically a spray composition. Homeopathic compositions have been described as being effective by delivering a small amount of a substance that in large quantities would create the symptom being observed thereby allowing the body to properly develop a response that ultimately is able to eliminate the cause of the symptom being observed. A wide variety of conditions as noted are treated using the homeopathic compositions, including back ache, muscle stiffness, pain reduction, swelling, inflammation, joint pain, localized musculoskeletal injuries like sprain, strains and many others.
Currently known topical analgesic products for pain management have many problems like unpleasant physical and social side effects such as strong odors, counter irritation, redness, itching, stinging, cooling, sensitization, staining, burning and anesthesia, etc. Thus, there exists a need for the development of a new, improved topical composition that would reduce the above associated side effects with improved patient compliance.
In consideration of the need as indicated above, the inventors of the present invention have done extensive research and conducted several experiments to develop a novel topical homeopathy synergistic composition of herbal extracts with lesser associated side effects thereby rendering the composition according to the present invention as an easy-to-use composition with optimum topical effects. Further, being devoid of lesser associated side effects, instant composition has more patient compliance even if it has repeated continuous long term usage.
Summary of the invention
In one aspect the invention provides a homeopathic composition comprising; i) Terminalia arjuna 2x to 8x; ii) Sticta pulmonaria 2x to 8x; iii) Colchicum autumnale 2x to 8x; iv) Gelsemium sempervirens 2x to 8x; v) Ledum palustre 2x to 8x; and vi) Cissus quadrangularis 2x to 8x.
In other aspect, the invention provides a homeopathic topical composition comprising:
(i) tinctures and/or homeopathic preparations of herbal extracts selected from the group consisting of Terminalia arjuna, Sticta pulmonaria, Colchicum autumnale, Gelsemium sempervirens, Ledum palustre and Cissus quadrangularis, (ii) biochemics; and
(iii) pharmaceutically acceptable vehicle or carrier medium for topical application as spray, cream, ointment, or gel for pain and/or inflammation
In another aspect, the homeopathic composition comprises: (i) tinctures and/or homeopathic preparations of herbal extracts selected from the group consisting of Terminalia arjuna, Sticta
pulmonaria, Colchicum autumnale, Gelsemium sempervirens, Ledum palustre and Cissus quadrangularis,
(ii) biochemics selected from Natrum muriaticum, Natrum phosphoricum; Magnesium phosphoricum or Natrum sulphuricum;
(iii) pharmaceutically acceptable vehicle or carrier medium.
In another aspect, the present invention provides a method of preparation of the homeopathic topical composition; comprising the steps of: a) Mixing the coarse powder of herbs ( Terminalia arjuna, Colchicum autumnale, Gelsemium sempervirens, Ledum palustre and Cissus quadrangularis ) with 70 % dispensing alcohol and 30 % purified water, setting the mixture in a glass column at room temperature and sealing the mouth of the column and setting aside for 48 hours; b) Adding Sticta pulmonaria under constant stirring to solution of step a; c) adding Natrum muriaticum to the solution of step b) under constant stirring; d) adding a secondary non-aqueous solution of Natrum phosphoricum with stirring for 5 - 10 minutes to the solution of step c); e) adding dispensing alcohol and allowing to disperse in the solution of step d); f) filtering the dispersion as obtained in step e) to obtain a clear solution of the composition; and g) adding glycerin (optionally) to the clear solution of step f) which is sonicated and filtered to obtain the composition.
In another aspect the homeopathic composition of the present invention is filled in containers fitted with spray nozzle.
In another aspect the homeopathic composition of the present invention is dispensed in cream, ointment or gel base.
In yet another aspect the homeopathic topical composition are useful in treating pain and/or inflammation, particularly to heal muscular and bone injuries.
Another aspect of the invention is a method of treating pain by administering an effective amount of a homeopathic topical composition to a subject in need thereof.
These and other aspects and advantages of the present invention will be apparent to those skilled in the art from the following description.
Detailed Description of the Invention
It should be understood that the detailed description and specific examples, while indicating embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art. One skilled in the art, based upon the definitions herein, may utilize the present invention to its fullest extent. The following specific embodiments are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
Unless otherwise defined, all the terms used herein, including the technical and scientific terms, have the meaning as that generally understood by one of ordinary skill in the art to which the present invention relates.
Definitions:
For the purpose of the disclosure, listed below are definitions of various terms used to describe the present invention. Unless otherwise indicated, these definitions apply to the terms as they are used throughout the specification and the appended claims, either individually or as part of a larger group. They should not be interpreted in the literal sense. They are not general definitions and are relevant only for this application.
It should be noted that, as used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the content clearly dictates otherwise.
It should be noted that the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
The terms "tincture" and "homeopathic formulation" of an herb refer to extracts of a part, combinations of parts and/or the entirety of the herb as described in Homeopathic Pharmacopoeia of India. The "tincture" can be prepared by exposing a part, parts and/or the entirety of the herb in a solvent, e.g. alcohol, glycerin and/or water. The "tincture" of an herb preferably is a mother tincture of the herb prepared according to the procedures in Homeopathic Pharmacopoeia of the United States (HPUS). The "homeopathic preparation" can be prepared by dilution of the "tincture" with an appropriate liquid such as water or alcohol. The "homeopathic preparation" of an herb for the formulation of the invention is preferably prepared as per HPUS procedures, wherein the mother tincture of the herb is serially diluted and subjected to succession according to the target potency using potentization procedures known in the art of homeopathy.
The term “potency” is defined as the strength of a homeopathic remedy which is determined by how many times the remedy has been succussed and diluted during
preparation. A number and a letter are associated with the remedy name to indicate which potency scale has been used. An example of the decimal scale would be Arnica Montana 6x. An example of the centesimal scale would be Arnica Montana 30c. An example of the 50 millesimal scale (LM) would be Arnica Montana LM1. These are the 3 potency scales currently in use. Further, for instance, an active drug at a potency of lx means that a tincture, preferably as defined in HPUS, of the active drug is diluted 1 in 10, e.g. 1 ml of the tincture is mixed with 9 ml of a diluent liquid, and then succussed at least 10 times, according to known potentization procedures in homeopathy. A potency of 2x means that the active drug having a potency of lx is further diluted 1 in 10 and then succussed at least 10 times yielding the active drug at 2x.
In the present invention, herbal extracts are selected from the group consisting of but not limited to Terminalia arjuna, Sticta pulmonaria, Colchicum autumnale, Gelsemium sempervirens, Ledum palustre and Cissus quadrangularis. The extracts of these herbs at the potencies disclosed below are used as active ingredients, which are mixed and blended with other ingredients in a vehicle to form a homeopathic composition.
In an embodiment, the potency of each one of the plurality of active ingredients included in the actives portion may be one of between about tincture to about 100x , between about 1 C to about 30 C, or about LM-1 to about LM-3.The potency of each one of the plurality of active ingredients included in the actives portion may be 8x , preferably 2x to 8x.
In an embodiment, a topical spray of instant homeopathic composition may include plurality of active ingredients i.e. tinctures and/or homeopathic preparations and biochemics; and a base including a plurality of inactive ingredients. The plurality of active ingredients include tinctures and/or homeopathic preparations of Terminalia arjuna, Sticta pulmonaria, Colchicum autumnale, Gelsemium sempervirens, Ledum palustre and Cissus quadrangularis; and biochemics selected from Natrum muriaticum, Natrum phosphoric or
Magnesium phosphoricum, Natrum sulphuricum, or Calcarea sulphurica; preferably Natrum muriaticum and Natrum phosphoricum.
In another embodiment the topical spray homeopathic formulations may include one, all, or any of the following:
The active ingredients include tinctures and/or homeopathic preparations selected from the group consisting of but not limited to herbal extracts selected from the group consisting of but not limited to Terminalia arjuna, Sticta pulmonaria, Colchicum autumnale, Gelsemium sempervirens, Ledum palustre and Cissus quadrangularis ; and biochemics selected from Natrum muriaticum, Natrum phosphoricum, Magnesium phosphoricum, Natrum sulphuricum, or Calcarea sulphurica.
Terminalia arjuna is a well known medicinal plant used in the ancient medicine. The bark of the tree is reported to contain many bioactive compounds, which can be tapped for use in the treatment of many diseases. Vagbhata mentions arjuna in the treatment of wounds, hemorrhages and ulcers, applied topically as a powder.
Sticta pulmonaria is used in inflammatory rheumatism of the knee joint.
Colchicum autumnale (Colchicum) is a toxic autumn-blooming flowering plant .
Gelsemium sempervirens ( Gelsemium ) is a twining vine native to warm temperate and tropical America, from Guatemala north to the southeastern USA. All parts of this plant contain the toxic strychnine-related alkaloids gelsemine, gelseminine and sempervirine . At pharmacological doses, G. sempervirens has been reported to show sedative, analgesic and anti- seizure properties.
Ledum palustre: Commonly known as marsh Labrador tea, northern Labrador tea or wild rosemary, is a flowering plant in the subsection Ledum of the large genus Rhododendron in the family Ericaceae. All parts of the plant contain
poisonous terpenes that affect the central nervous system a very valuable remedy for rheumatism
Cissus quadrangularis a traditional medicine for joint and bone health (as well as various feminine disorders and menopause), and shows promise in promoting bone growth rates. It is popular as a joint aid for athletes, with preliminary evidence supporting this property of cissus.
The process of Cissus quadrangularis extraction used in the composition is cold extraction.
Dried Cissus quadrangularis is cleaned and macerated into pieces. 100 gm of Cissus is sonicated with alcohol and water at room temperature, post it settling down it is set in open column with Ethanol and Water if required, the column is set sealed. Post 36 hours the elute is collected and sieved. It is filtered using vaccum filtration post 24 hrs.
The inactive ingredients include menthol, alcohol, glycerin and water.
Magnesium phosphoricum, Natrum sulphuricum, Calcarea sulphurica are used as it brings in synergistic effect along with the herbs.
According to an embodiment the examples of topical preparations include ointment, cream, gel, spray, etc. The most preferred being application being topical spray for treating pain and/or inflammation.
The topical spray compositions of present invention may be applied onto the skin by using a sprayable dispensing device. Preferably, dispensed in a container such as a bottle or the like, fitted with a pump dispenser / nozzle or a manual metered pump that delivers a metered unit dose on actuation.
According to an embodiment the composition of the present invention contains a thickening agent or polymeric material dissolved or suspended in a liquid to yield a gel based composition. The observed effectiveness of a given homeopathic preparation can depend upon the method used to administer it to the patient. For example, lower potency (higher concentration) homeopathic ingredients appear to have better results when used as a topical treatment application when compared to high potency ingredients. In contrast, high potency homeopathic ingredients work well when administered orally or internally.
The various components included in implementations of homeopathic preparations disclosed here are selected from those officially listed in the Homeopathic Pharmacopoeia of the United States (HPUS) and Homeopathic Pharmacopoeia of India. Table 1 is a listing of all active ingredients (components) that may be used in the various preparations of the instant invention along with the range of dilutions that may be utilized for each. In this table, tincture refers to the mother tincture as defined in the HPUS.
TABLE 1 - Active Ingredient
A wide variety of combinations of potential active ingredients at desired potencies are possible using the ingredients and dilutions listed in Table 1. In the instant invention, various implementations of a topical spray preparation, and/or bottle containing a dispensing dropper preparation and/or in a roll-on bottle and/or in any form of creams or ointments or serums or oils or emulsifications are disclosed. Those of ordinary skill in the art will readily be able to create additional implementations using the principles disclosed herein.
According to an embodiment of the present invention there is provided a homeopathic composition comprising i) Terminalia arjuna 2x to 8x; ii) Sticta pulmonaria 2x to 8x; iii) Colchicum autumnale 2x to 8x; iv) Gelsemium sempervirens 2x to 8 x; v) Ledum palustre 2x to 8x; and vi) Cissus quadrangularis 2 x to 8 x.
According to an embodiment of the present invention the composition may comprise biochemics and pharmaceutically acceptable vehicle or carrier.
The composition of the present invention is an effective formulation that does not have toxicity and tackles pain and inflammation effectively.
Table 4 - Actives preparation as per Monograph from HPI Voll (Parti)
TABLE 5 -Base Implementation
Process for the preparation of Composition of the Present invention :
In an aspect, the present invention i) all the herbs namely Terminalia arjuna, Sticta pulmonaria, Colchicum autumnale, Gelsemium sempervirens, LedumP alustere and Cissus quadrangularis are measured to 50 gm individually. Columns are setup and each herb is set in the column with purified water and alcohol in ratio of 30:70. The columns are sealed pack and kept for 48 hours. ii) Biochemics like Natrum muriaticum, Natrum phosphoricum, Magnesium phosphoricum, Natrum sulphuricum, Calc area sulphurica are added to the column of Cissus quadrangularis. iii) Elute is filtered. All elutes are then mixed in equal proportions. All elutes are then mixed in equal proportions. Purified water is added to the mixture of elutes. It is again filtered. Menthol is added by dissolving it in alcohol. Glycerin is added and entire solution is sonicated
In an aspect, the present invention relates to a process for the preparation of a homeopathic topical composition comprising the steps of: a) Mixing the coarse powder of herbs ( Terminalia arjuna, Colchicum autumnale, Gelsemium sempervirens, Ledum palustre and Cissus quadrangularis) with 70 % dispensing alcohol and 30 % purified water, setting the mixture in a glass column at room temperature and sealing the mouth of the column and setting aside for 48 hours; b) adding Sticta pulmonaria under constant stirring to solution of step a) c) adding Natrum muriaticum to the solution of step b) under constant stirring; d) adding a secondary non-aqueous solution of Natrum phosphoricum with stirring for 5 - 10 minutes to the solution of step c); e) adding dispensing alcohol and allowing to disperse in the solution of step d);
f) filtering the dispersion as obtained in step e) to obtain a clear solution of the composition.
In another embodiment of the present invention glycerin is added to the clear solution of step f) which is sonicated and filtered to obtain the composition.
It will be evident to one skilled in the art that the present invention is not limited to the above description or illustrative examples provided below, and that it can be embodied in other specific forms without departing from the essential attributes thereof. It is therefore desired that the description and examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein. Accordingly, the following examples are intended to illustrate but not to limit the scope of the present invention.
Examples in accordance with the present invention Example 1:
The topical composition of Homeopathy composition
Procedure: a. 200 ml of Cissus quadrangularis extract made in House and 100 ml of Ledum Palustre added in a beaker, b. Half of 50 ml each of { Magnesium phosphoricum + Natrum sulphuricum + Calcarea sulphurica} was added to it (liquids), c. Dispensing Alcohol (70%) + Purified Water (30%) was added, d. The resulting solution was allowed to attain a temperature of 20- 25°C. e. The dispersion as obtained in step (d) was homogenized for 15 minutes at 4200 rpm and stirred for 120 minutes and filtered one or more times through PES filter to obtain a clear solution,
Filtered twice to get clear solution f. 100 ml of extract made In House of Terminalia Arjuna was added to the above solution g. 100 ml of mother tincture of Sticta pulmonaria and gelsemium was added to the above solution h. 100 ml of extract made In House of Colchicum were added to the solution i. The resulting solution was allowed to attain a temperature of 20- 25°C. j. The dispersion as obtained in step (i) was sonicated for 15 minutes stirred for 120 minutes and filtered one or more times through PES filter to obtain a clear solution, k. Other half of 50 ml each of { Magnesium Phosphoricum + Natrum Sulphuricum + Calcarea Sulphurica} added to it (liquids) l. The resulting solution was allowed to attain a temperature of 20- 25°C. m. The dispersion as obtained in step (1) was sonicated for 15 minutes stirred for 120 minutes and filtered one or more times through PES filter to obtain a clear solution,
Elute:
Cissus quadrangularis 200 ml Q Ledum palustre 100 ml Q Terminalia arjuna 100 ml Q Sticta pulmonaria 100 ml Q
Gelsemium 100 ml Q Colchicum 100 ml Q
10 mg of Menthol dissolved in 100 ml of Purified Water Example 2:
Procedure: a. 200 ml of Cissus quadrangularis extract made in House and 100 ml of Ledum palustre extract made In House was added in a beaker b. Half of 50 ml each of { Magnesium phosphoricum + Natrum sulphuricum + Calcarea sulphurica} was added to it (liquids),
c. Dispensing Alcohol (70%) + Purified Water (30%) was added, d. The resulting solution was allowed to attain a temperature of 20- 25°C. e. The dispersion as obtained in step (d) was homogenized for 15 minutes at 4200 rpm and stirred for 120 minutes and filtered one or more times through PES filter to obtain a clear solution,
Filtered twice to get clear solution f. 100 ml of extract made In House of Terminalia Arjuna was added to the above solution g. 100 ml of mother tincture of Sticta pulmonaria and Gelsemium was added to the above solution h. 100 ml of extract made In House of Colchicum were added to the solution i. The resulting solution was allowed to attain a temperature of 20- 25°C. The dispersion as obtained in step (e) was sonicated for 15 minutes stirred for 120 minutes and filtered one or more times through PES filter to obtain a clear solution, j. Other Half of 50 ml each of {Magnesium Phosphoricum + Natrum Sulphuricum + Calcarea Sulphurica} added to it (liquids) k. The resulting solution was allowed to attain a temperature of 20- 25°C. l. The dispersion as obtained in step (j) was sonicated for 15 minutes stirred for 120 minutes and filtered one or more times through PES filter to obtain a clear solution,
Elute:
Cissus quadrangularis 200 ml Q
Ledum palustre 100 ml Q
Terminalia arjuna 100 ml Q
Sticta pulmonaria 100 ml Q
Gelsemium 100 ml Q
Colchicum 100 ml Q
20 mg of Menthol dissolved in 100 ml of Purified Water
Procedure: a. 200 ml of Cissus quadrangularis extract made In House was and 100 ml of Ledum palustre extract made In House added in a beaker b. Half of 50 ml each of {Magnesium phosphoricum + Natrum sulphuricum + Calcareasulphurica} was added to it (liquids), c. Dispensing Alcohol (70%) + Purified Water (30%) was added, d. The resulting solution was allowed to attain a temperature of 20- 25°C. The dispersion as obtained in step (e) was homogenized for 15 minutes at 4200 rpm and stirred for 120 minutes and filtered one or more times through PES filter to obtain a clear solution, Filtered twice to get clear solution
e. 100 ml of mother tincture of Terminalia Arjuna was added to the above solution f. 100 ml of mother tincture of Sticta pulmonaria was added to the above solution g. 100 ml of mother tincture of each Gelsemium and Colchicum were added to the solution h. The resulting solution was allowed to attain a temperature of 20- 25°C. The dispersion as obtained in step (g) was sonicated for 15 minutes stirred for 120 minutes and filtered one or more times through PES filter to obtain a clear solution, i. Other half of 50 ml each of { Magnesium Phosphoricum + Natrum Sulphuricum + Calcarea Sulphurica} added to it (liquids) j. Glycerin was added to the solution to increase the viscosity. k. The resulting solution was allowed to attain a temperature of 20- 25°C. l. The dispersion as obtained in step (k) was sonicated for 15 minutes stirred for 120 minutes and filtered one or more times through PES filter to obtain a clear solution.
Elute:
Cissus quadrangularis 200 ml Q Ledum palustre 100 ml Q Terminalia arjuna 100 ml Q Sticta pulmonaria 100 ml Q Gelsemium 100 ml Q Colchicum 100 ml Q
20 mg of Menthol dissolved in 100 ml of Purified Water 10 ml of Glycerin The clear solution obtained above is filled in spray bottles. The composition of the present invention is applied topically by means of a spray.
In embodiment the clear solution obtained above is mixed with gel base for topical administration.
In embodiment the clear solution obtained above is mixed with cream base for topical administration.
Evaluation of Anti-inflammatory and Analgesic activity of topical formulations:
Experiment 1 Anti-inflammatory activity of Formulations on carrageenan-induced paw edema in rats
Anti-inflammatory activity of different formulations was evaluated in carrageenan-induced paw edema in male Sprague-Dawley rats weighing about 225g. Thirty minutes before carrageenan injection, the formulations VP2, VP3 were applied on the left hind paw of the rats at the dose of 0.35ml. Control group received vehicle only.
Each group had 6 animals.
Then, 0.1 ml of 1% carrageenan in physiological saline was injected into the paw subplantarly. Immediately,!, 2, 3 and 4hours after the carrageenan injection, the thickness of the paw was measured using a digital vernier caliper, and the percent swelling of the paw and the percent inhibition of the edema formation were calculated as follows:
% swelling at a timepoint = [(paw thickness - initial paw thickncssj/initial paw thickness] x 100 % inhibition = [1- (% swelling of drug-treated group/% swelling of control group)] x 100
The results are represented in table 6
Table 6. Effect of formulations on carrageenan-induced paw edema
* p <0.05 vs. control group (One-way ANOVA, followed by Dunnett's post hoc test)
As can be seen in Table 6, the formulations according to the present invention exhibited significant decrease of % swelling of the paw compared to the control. The % inhibition of the edema formation by the formulations was maximum with VP2, which is in range of 44.82% to 53.31.
In formulation without Sticta and Colchicum, there was significant drop in the activity noted.
Experiment 2
Analgesic activity of Formulations on carrageenan-induced paw edema in rats
Analgesic activity was evaluated against hypernociception induced in the hindpaw by the administration of an intraplantar carrageenan suspension and was measured according to the paw pressure tests of Randall Selitto. In the Randall Selitto test, an analgesy-meter with a cone-shaped paw-presser with a rounded tip, which applies a linearly increasing force to the plantar surface of the paw, was used. The weight in grams (g) required to elicit nociceptive responses such as paw flexion or struggling was defined as the nociceptive threshold. The mechanical evaluation of hypernociception intensity was evaluated 3 hrs after the carrageenan injection.
The results are represented in table 7.
Table 7. The mechanical evaluation of formulations against hypernociception intensity (A withdrawal threshold in grams)
* p <0.05 vs. control group (One-way ANOVA, followed by Dunnett's post hoc test)
As can be seen in Table 7, the formulations according to the present invention exhibited significant attenuation of D withdrawal threshold compared to the control group.
Maximum attenuation was observed with the formulationVP2.
Experiment 2
Skin irritation study in rabbits
The acute dermal irritation study was performed in accordance with the OECD Guidelines 404 for “Acute dermal irritation/corrosion” on male White New Zealand rabbits (2.5-3 kg). Briefly, approximately 24 hours before the test, around 5 cm x 5 cm of rabbit’s dorsal area of the trunk was clipped for experimental use.
0.5 ml formulation was then applied under a 2.5 cm x 2.5 cm gauze patch and wrapped with occlusive dressing. The test sites were observed and scored for erythema and oedema at 1 h, 24 h, 48 and 72 h post-exposure with formulation. Dermal responses were determined in accordance with OECD guidelines. Erythema and oedema were scored on a scale of 0-4, with 0 showing no effect and 4 representing severe symptoms. Since formulation was expected to be safe, limit test was performed in one rabbit as per OECD guideline 404.
As can be seen in Table 8, formulation did not show any signs of irritations till 72 hrs post-exposure.
Thus the topical formulation of the present invention is safe.
Although shown and described in what is believed to be the most practical and preferred embodiments, departures from the specific formulation and process described may be apparent to those skilled in the art and may be used without departing from the scope of the present invention.
Claims
1. A homeopathic composition comprising; i) Terminalia arjuna 2x to 8x; ii) Sticta pulmonaria 2x to 8x; iii) Colchicum autumnale 2x to 8x; iv) Gelsemium sempervirens 2x to 8x v) Ledum palustre 2x to 8x; and vi) Cissus quadrangularis 2x to 8x.
2. A homeopathic composition comprising a) Tinctures or homeopathic preparation of herbal extracts comprising; i) Terminalia arjuna ; ii) Sticta pulmonaria, iii) Colchicum autumnale; iv) Gelsemium sempervirens, v) Ledum palustre and vi) Cissus quadrangularis b) biochemics; and c) pharmaceutically acceptable vehicle or carrier
3. The homeopathic composition as claimed in claim 2 wherein the biochemics is selected from Natrum muriaticum, Natrum phosphoric, Magnesium phosphoricum, Natrum sulphuricum,or Calcarea sulphurica.
4. The homeopathic composition as claimed in claim 2 wherein the pharmaceutically acceptable vehicle or carrier is selected from menthol, alcohol, glycerin or water.
5. The homeopathic composition as claimed in claims 1 to 4 wherein the formulation is in the form of spray, cream, ointment or gel.
6. The process for preparing homeopathic composition as claimed in claim 2 comprising steps of: a) Mixing the coarse powder of herbs Terminalia arjuna, Colchicum autumnale, Gelsemium sempervirens, Ledum palustre and Cissus quadrangularis with 70 % dispensing alcohol and 30 % purified water, setting the mixture in a glass column at room temperature and sealing the mouth of the column and setting aside for 48 hours; b) Adding Sticta pulmonaria under constant stirring to solution of step a); c) adding Natrum muriaticum to the solution of step b) under constant stirring; d) adding a secondary non-aqueous solution of Natrum phosphoricum with stirring to the solution of step c); e) adding dispensing alcohol and allowing to disperse in the solution of step d); f) filtering the dispersion obtained in step e) to obtain a clear solution of the composition.
7. The process for preparing homeopathic composition as claimed in claim 6 where in glycerin is added to the clear solution of step (f) which is sonicated and filtered to obtain the composition.
8. The process for preparing homeopathic composition as claimed in claim 6 and 7 wherein the composition is mixed with gel base or cream base to give topical gel formulation and topical cream formulation respectively.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3161854A CA3161854A1 (en) | 2019-11-14 | 2020-11-13 | Homeopathic topical composition |
EP20886714.3A EP4058039A4 (en) | 2019-11-14 | 2020-11-13 | Homeopathic topical composition |
US17/777,170 US20220395574A1 (en) | 2019-11-14 | 2020-11-13 | Homeopathic topical composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201921046308 | 2019-11-14 | ||
IN201921046308 | 2019-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021094989A1 true WO2021094989A1 (en) | 2021-05-20 |
Family
ID=75913000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2020/060686 WO2021094989A1 (en) | 2019-11-14 | 2020-11-13 | Homeopathic topical composition |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220395574A1 (en) |
EP (1) | EP4058039A4 (en) |
CA (1) | CA3161854A1 (en) |
WO (1) | WO2021094989A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2518965C (en) * | 2003-03-14 | 2018-10-30 | Nutrition Research Inc. | Homeopathic formulations useful for treating pain and/or inflammmation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN188857B (en) * | 2000-07-14 | 2002-11-16 | Govind Kane Dr Shantaram | |
US20060165812A1 (en) * | 2005-01-21 | 2006-07-27 | Amershire Investment Corporation | Method and topical formulation for treating headaches |
US11123414B2 (en) * | 2017-12-22 | 2021-09-21 | Produits Naturasense Inc. | Non-carcinogenic cream for delivery of active ingredient into the dermis |
CA2989926C (en) * | 2017-12-22 | 2024-01-02 | Produits Naturasence Inc. | Non-carcinogenic cream for delivery of active ingredient into the dermis |
-
2020
- 2020-11-13 CA CA3161854A patent/CA3161854A1/en active Pending
- 2020-11-13 WO PCT/IB2020/060686 patent/WO2021094989A1/en unknown
- 2020-11-13 US US17/777,170 patent/US20220395574A1/en active Pending
- 2020-11-13 EP EP20886714.3A patent/EP4058039A4/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2518965C (en) * | 2003-03-14 | 2018-10-30 | Nutrition Research Inc. | Homeopathic formulations useful for treating pain and/or inflammmation |
Non-Patent Citations (7)
Title |
---|
"TKDL AA11/822", DAWA BARA-E- WAJA-E- NIQRAS, KNOWLEDGE KNOWN SINCE 1000 YEARS, XP055825176, Retrieved from the Internet <URL:http://www.tkdl.res.in> * |
"TKDL BM01/322", PIRANDAI, KNOWLEDGE KNOWN SINCE 1000 YEARS, XP055825181, Retrieved from the Internet <URL:http://www.tkdl.res.in/).> * |
ANONYMOUS: "MAGNESIUM PHOSPHORICUM", DR. WILLMAR SCHWABE INDIA, DR. WILLMAR SCHWABE INDIA, INDIA, India, pages 1 - 5, XP009537195, Retrieved from the Internet <URL:https://www.schwabeindia.com/95-magnesium-phosphoricum.html> * |
DR. RECKEWEG: "Dr. Reckeweg Sticta Pulmonaria 200 CH (11ml) : For Bronchial catarrh, Sinusitis, Headache and Joint Pain", SHOPHEALTHY, India, XP009537193, Retrieved from the Internet <URL:https://www.shophealthy.in/reckeweg-sticta-pulmonaria-200chdilution> * |
OLIOSO, DEBORA ET AL.: "Effects of Gelsemium sempervirens L. on pathway-focused gene expression profiling in neuronal cells", JOURNAL OF ETHNOPHARMACOLOGY, vol. 153, no. 2, 2014, pages 535 - 539, XP028847715 * |
PAARAKH, PADMAA M. ET AL.: "Terminalia arjuna (Roxb.) Wt. and Arn.: a review.", IJP-INTERNATIONAL JOURNAL OF PHARMACOLOGY 6.5, 14 July 2010 (2010-07-14), pages 515 - 534, XP055824208 * |
See also references of EP4058039A4 * |
Also Published As
Publication number | Publication date |
---|---|
CA3161854A1 (en) | 2021-05-20 |
EP4058039A4 (en) | 2023-12-27 |
EP4058039A1 (en) | 2022-09-21 |
US20220395574A1 (en) | 2022-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3705151A1 (en) | WARTS | |
WO2012131732A1 (en) | A synergistic herbal extract composition for use in treating and preventing mastitis | |
CN1084765A (en) | Stasis-removing bone-setting medicine | |
CN105148059A (en) | Plant oil external liniment capable of repelling mosquitos and preparation method thereof | |
US9545429B1 (en) | Homeopathic formulations | |
CN108578465A (en) | A kind of Chinese medicine composition and its preparation method and application | |
CN103520406A (en) | Traditional Chinese medicinal pigmentum for treating eczema and preparation method thereof | |
CN109498549A (en) | A kind of ozone oil compound hemorrhoidal cream and preparation method thereof | |
CN103223015A (en) | Muscle soreness and skin itch treatment drug composition and preparation method thereof | |
CN110974861B (en) | Blumea balsamifera oil liposome | |
WO2021094989A1 (en) | Homeopathic topical composition | |
CN103239594B (en) | Topical pharmaceutical composition for preventing and treating canine acariasis disease and preparation method thereof | |
CN110025705A (en) | A kind of Chinese medicine composition and its preparation method and application for treating atopic dermatitis | |
CN103585330B (en) | A kind of Chinese medicine composition for cutaneous fungal infection and preparation method thereof | |
CN1055115A (en) | Preparation method of ointment for treating scabies of livestock | |
CN101700331B (en) | Bone joiner spray | |
RU2635459C1 (en) | Drug with spasmolithic, diuretic and lithiolic action | |
WO2011070096A1 (en) | Compound for treating gastrointestinal problems | |
Karande et al. | Medicinal Plants Diversity in Nashik District (Maharashtra: India)-Polypetalae& Gamopetalae | |
CN101468055A (en) | Gel patch for preventing and treating cerebral thrombosis and preparation method thereof | |
CN108434299B (en) | Pharmaceutical composition for treating scapulohumeral periarthritis and preparation method and spray thereof | |
CN100496600C (en) | Medicine for treating osteoporosis and its preparation method | |
CN100341532C (en) | External use preparation for treating bliser tetter | |
CN106074995A (en) | A kind of bactericidal composition for treating female sex organs inflammation and application thereof | |
CN104800422A (en) | Tea tree essential oil for treating groin tinea and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20886714 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3161854 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020886714 Country of ref document: EP Effective date: 20220614 |